Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.

doi:10.1016/j.ejmech.2016.02.039

Paper

Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.

Published Jun 10, 2016 · Ashraf K. El-Damasy, Ju‐Hyeon Lee, S. Seo

European journal of medicinal chemistry

Q2 SJR score

52

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Study Snapshot

The new series of benzothiazole amide and urea derivatives with pyridylamide moiety show potential as potent anticancer drugs with extended spectrum activity and low drug-drug interactions and cardiac side effects.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.

References

Citations